Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × CT-322 × Clear all
NCT00851045 2015-10-12

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Bristol-Myers Squibb

Phase 2 Completed
17 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00374179 2009-02-24

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡